Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|PD-L1 Negative
Interventions: DRUG: Sacituzumab Govitecan-hziy|DRUG: Paclitaxel|DRUG: nab-Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin
Sponsor: Gilead Sciences